Enanta Pharmaceuticals (ENTA) Price & Analysis

Compare

179 Followers

ENTA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.09 - $13.50

Previous CloseN/A

Volume330.58K

Average Volume (3M)167.75K

Market Cap

$158.40M

Enterprise Value$140.65M

Total Cash (Recent Filing)$193.38M

Total Debt (Recent Filing)$58.73M

Price to Earnings (P/E)―

Beta1.64

Next Earnings

Aug 11, 2025

EPS Estimate

-0.9

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.06

Shares Outstanding21,376,581

10 Day Avg. Volume161,000

30 Day Avg. Volume167,751

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.89

Enterprise Value/Revenue2.18

Enterprise Value/Gross Profit2.18

Enterprise Value/Ebitda-1.61

Forecast

1Y Price Target

$17.75

Price Target Upside139.54% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Financial StabilityEnanta received a $33.8M federal income tax refund, strengthening their balance sheet.

Pipeline PotentialENTA shares offer a favorable risk-reward profile at current share levels, driven by upcoming clinical catalysts and a diversified pipeline in virology and immunology.

Regulatory ProgressZelicapavir successfully met the study's primary virology endpoint in the pooled efficacy population, with a peak viral load reduction of 0.7 log on Day 9 compared to placebo.

Bears Say

Market ValuationEnanta shares have settled near multi-year lows with a lack of late-stage catalysts and visibility to approvals/market.

Regulatory ChallengesClarity is needed for symptom improvement with zelicapavir, as there are no regulatory-approved symptom assessment tools for pediatric RSV currently.

Enanta Pharmaceuticals News

Enanta assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Brandon Folkes assumed coverage of Enanta (ENTA) with a Buy rating and $20 price target...

11d ago

ENTA

Enanta price target raised to $24 from $23 at Citizens JMP

Citizens JMP analyst Roy Buchanan raised the firm’s price target on Enanta (ENTA) to $24 from $23 and...

2M ago

ENTA

Enanta price target raised to $23 from $21 at Citizens JMP

Citizens JMP raised the firm’s price target on Enanta (ENTA) to $23 from $21 and keeps an Outperform...

3M ago

ENTA

Enanta Pharmaceuticals Reports Q2 2025 Financial Results

Enanta Pharmaceuticals ( ($ENTA) ) has released its Q2 earnings. Here is a breakdown of the information Enanta...

3M ago

ENTA

Enanta reports Q2 EPS ($1.06), consensus ($1.14)

Reports Q2 revenue $14.9M, consensus $16.0M. “Throughout the fiscal second quarter, Enanta (ENTA) remained squarely focused on executing...

3M ago

ENTA

Is ENTA a Buy, Before Earnings?

Enanta Pharmaceuticals (ENTA) is scheduled to report 2nd quarter earnings on 05/12/2025. Regarding Q2 estimates, Wall Street analysts...

3M ago

ENTA

Enanta Pharmaceuticals Stockholders Approve Key Proposals in 2025

An announcement from Enanta Pharmaceuticals ( ($ENTA) ) is now available. At the Annual Meeting on March 13,...

5M ago

ENTA

Enanta Pharmaceuticals: Hold Rating Amid Delayed Launches and Strategic Advancements

Enanta Pharmaceuticals (ENTA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on...

5M ago

ENTA

Enanta Pharmaceuticals Advances in Virology and Immunology

Enanta Pharmaceuticals ( ($ENTA) ) has released its Q1 earnings. Here is a breakdown of the information Enanta...

6M ago

ENTA

Enanta CEO buys $256K in common stock

In a regulatory filing, Enanta (ENTA) disclosed that its CEO Jay Luly bought 45K shares of common stock...

6M ago

ENTA

Enanta Pharmaceuticals: Buy Rating Driven by Promising RSV Developments and Strategic Plans

Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Enanta Pharmaceuticals (ENTA – Research Report), retaining...

6M ago

ENTA

Enanta reports Q1 EPS ($1.05), consensus ($1.35)

Reports Q1 revenue $17M, consensus $17.25M. “2025 is primed to be a pivotal year for Enanta (ENTA) as...

6M ago

ENTA

Enanta Pharmaceuticals (ENTA) Q1 Earnings Cheat Sheet

Enanta Pharmaceuticals (ENTA) is scheduled to report 1st quarter earnings on 02/05/2025. Regarding Q1 estimates, Wall Street analysts...

6M ago

ENTA

Enanta to appeal ruling related to ‘953 patent infringement lawsuit

Enanta Pharmaceuticals (ENTA) announced that the United States District Court of Massachusetts has issued a ruling on a...

8M ago

PFE

ENTA

ENTA FAQ

What was Enanta Pharmaceuticals’s price range in the past 12 months?

Enanta Pharmaceuticals lowest stock price was $4.09 and its highest was $13.50 in the past 12 months.

What is Enanta Pharmaceuticals’s market cap?

Enanta Pharmaceuticals’s market cap is $158.40M.

When is Enanta Pharmaceuticals’s upcoming earnings report date?

Enanta Pharmaceuticals’s upcoming earnings report date is Aug 11, 2025 which is in 3 days.

How were Enanta Pharmaceuticals’s earnings last quarter?

Enanta Pharmaceuticals released its earnings results on May 12, 2025. The company reported -$1.06 earnings per share for the quarter, beating the consensus estimate of -$1.147 by $0.087.

Is Enanta Pharmaceuticals overvalued?

According to Wall Street analysts Enanta Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Enanta Pharmaceuticals pay dividends?

Enanta Pharmaceuticals does not currently pay dividends.

What is Enanta Pharmaceuticals’s EPS estimate?

Enanta Pharmaceuticals’s EPS estimate is -0.9.

How many shares outstanding does Enanta Pharmaceuticals have?

Enanta Pharmaceuticals has 21,376,581 shares outstanding.

What happened to Enanta Pharmaceuticals’s price movement after its last earnings report?

Enanta Pharmaceuticals reported an EPS of -$1.06 in its last earnings report, beating expectations of -$1.147. Following the earnings report the stock price went down -5.766%.

Which hedge fund is a major shareholder of Enanta Pharmaceuticals?

Currently, no hedge funds are holding shares in ENTA

Enanta Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-74.26%

Trailing 12-Months

Asset Growth

-21.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Enanta Pharmaceuticals (ENTA) Earnings & Revenues

Historic Earnings Reports

ENTA Stock 12 Month Forecast

Average Price Target

$17.75

▲(139.54% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","25":"$25","9.25":"$9.25","14.5":"$14.5","19.75":"$19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9.25,14.5,19.75,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.7,8.953846153846154,10.207692307692309,11.461538461538462,12.715384615384615,13.96923076923077,15.223076923076924,16.476923076923075,17.73076923076923,18.984615384615385,20.23846153846154,21.49230769230769,22.746153846153845,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.7,8.473076923076924,9.246153846153847,10.01923076923077,10.792307692307693,11.565384615384616,12.338461538461539,13.111538461538462,13.884615384615385,14.657692307692308,15.430769230769231,16.203846153846154,16.97692307692308,{"y":17.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.7,7.6461538461538465,7.592307692307693,7.538461538461538,7.484615384615385,7.430769230769231,7.376923076923077,7.323076923076923,7.269230769230769,7.2153846153846155,7.161538461538462,7.107692307692307,7.053846153846154,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.47,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.81,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.94,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.95,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.57,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.75,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.11,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.78,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.32,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >